Decision on orphan drug designation for NTI164 to treat Rett syndrome expected in ‘due course’ US Food and Drug Administration granted orphan designation for NTI164 in Rett syndrome in ...
Barcelona, Spain – 5 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback